Brief: Mirati Presents Late-Breaking Results Evaluating The Combination Of Adagrasib And Pembrolizumab In First-Line Non-Small Cell Lung Cancer (Nsclc)
17/10/2023 21:10
Oct 17 (Reuters) - Mirati Therapeutics Inc MRTX.O :
* MIRATI PRESENTS LATE-BREAKING RESULTS EVALUATING THE
COMBINATION
OF ADAGRASIB AND PEMBROLIZUMAB IN FIRST-LINE NON-SMALL CELL LUNG
CANCER (NSCLC)
* MIRATI THERAPEUTICS INC: SAFETY PROFILE OF ADAGRASIB AND
PEMBROLIZUMAB COMBINATION WAS CONSISTENT WITH EITHER AGENT AS
MONOTHERAPY
* MIRATI THERAPEUTICS INC: PLANS TO INITIATE A PHASE 3
CLINICAL
STUDY TO EVALUATE ADAGRASIB IN COMBINATION WITH PEMBROLIZUMAB
* MIRATI THERAPEUTICS INC: INITIAL PATIENT ENROLLMENT IS
EXPECTED
BY YEAR-END 2023
Source text for Eikon: ID:nPnbHflbGa
Further company coverage: MRTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mirati Therapeutics
See all newsBrief: European Commission Approves KRAZATI As A Targeted Treatment For Non-Small Cell Lung Cancer
US FDA turns down Amgen lung cancer drug Lumakras for full approval (updated)
US FDA turns down Amgen lung cancer drug Lumakras for full approval
Brief: Mirati Stockholders Voted 'For' Proposal To Adopt Deal Between Co, Bristol-Myers Squibb
Mirati's lung cancer drug gets EU's regulatory backing (updated)